Gina Shishima is Head of IP Transactions and Patent Prosecution, United States, and is also Norton Rose Fulbright's US Chief Diversity Officer.
Gina's practice is in the area of patent law – both transactional and litigation – with a primary focus in the medical, biotechnology, and pharmaceutical fields. She has patent prosecution experience that includes patent portfolio management and patent counseling, as well as involvement in inter partes reviews (IPR), reexaminations, interferences, and European oppositions. Other experience includes a wide variety of involvement in patent litigation matters and licensing issues. In addition, Gina has experience in patentability opinions, freedom to operate evaluations, intellectual property due diligence and competitive technology assessments.
In the course of her patent litigation and prosecution work, Gina has worked on a variety of areas in biotechnology and pharmaceutics such as: therapeutics, diagnostics, and prognostics, nucleic acid and protein therapies, small molecule therapies, immunotherapies, virus-based applications, therapeutic formulations and delivery systems, vaccine applications, transgenic organisms, drug screening, molecular biology reagents, and pharmacogenomics (personalized medicine). In addition, her litigation and prosecution experience extends into the areas of medical devices and apparatuses (including PET scanning technology, radiation phantoms, stents and microfluidics sensor technology), business patents and computer hardware.